Print this page    •   Back to Web version of article

In the Dog House: Hoffman-La Roche

January 2003

In the Dog House: Hoffman-La Roche Hoffmann-La Roche, maker of saquinavir (Invirase and Fortovase) and ddC (HIVID) for setting the price of their new drug for hepatitis C, called Pegasys, even higher than that charged by Schering Plough for a similar drug.

Schering's price, at around $14,000 per year, was already so high that most people considered it immoral, but despite the impending crisis in funding for drugs, Roche topped them, charging nearly $15,000. Pegasys must be used in combination with a second drug, ribavirin, so the true price is higher still.

Want to tell them how you feel about this? Write or email:
George Abercrombie
President & CEO
Hoffmann-La Roche
340 Kingsland St.
Building 85, 8th Floor
Nutley, NJ 07110
george.abercrombie@roche.com


Back to the Project Inform Perspective January 2003 contents page.




This article was provided by Project Inform. It is a part of the publication Project Inform Perspective. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art5595.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.